Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012194 · ClinicalTrials.gov registry record · Phase 1
7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00012194: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00012194 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00012194, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of combining UCN-01 with cisplatin in treating patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help cisplatin kill more cancer cells by making tumor cells more sensitive to the drug.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cisplatin
- DRUG 7-hydroxystaurosporine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012194
The ClinicalTrials.gov registry entry for NCT00012194 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00012194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012194 about?
NCT00012194 is a clinical study titled "7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors". Phase I trial to study the effectiveness of combining UCN-01 with cisplatin in treating patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may stop the growth of tumor cells by blocking the enzy...
What is the current status of trial NCT00012194?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2001-03.
What interventions are being tested in trial NCT00012194?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), 7-hydroxystaurosporine (DRUG).
Who is sponsoring clinical trial NCT00012194?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.